Clinical trials: Pulmonary Fibrosis
Cystic Fibrosis
Safety and Tolerability Trial of Inhaled Alpha1-Proteinase Inhibitor (Human), Hydrophobic Chromatography Process (Alpha-1 HC) in Subjects With Cystic Fibrosis
This was a randomized, double-blind, placebo-controlled, dose escalation study to assess the safety and tolerability of 100 mg and 200 mg of inhaled Alpha-1 HC administered once a day for three weeks in subjects aged 18 years and…
- Trial name
- NCT01684410
- Testing
- Alpha-1 HC 100 mg, Alpha-1 HC 200 mg
- Where
- 6 sites in United States
- Volunteers
- 30 people
- Sponsor
- Grifols Therapeutics LLC
Fibrosis
First in Human Study in Healthy Volunteers Followed With Dosing in Participants With Lung or Liver Fibrosis
First in Human single ascending dose followed by multiple ascending doses in healthy volunteers.
- Trial name
- NCT03559166
- Testing
- BLD-2660
- Where
- Australia
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Blade Therapeutics
Cystic Fibrosis
Study Assessing PTI-428 Safety, Tolerability, and Pharmacokinetics in Subjects With Cystic Fibrosis on KALYDECO® as Background Therapy
The trial will consist of a single treatment group enrolling adult subjects with CF on background therapy with KALYDECO®. Approximately 16 subjects will be enrolled.
- Trial name
- NCT03258424
- Testing
- PTI-428
- Where
- 2 sites in United Kingdom
- Volunteers
- 15 people
- Sponsor
- Proteostasis Therapeutics, Inc.
Cystic Fibrosis
Evaluation of VX-581 in Healthy Participants and in Participants With Cystic Fibrosis
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of single dose of VX-581 and multiple ascending doses of VX-581 alone and in combination with tezacaftor (TEZ)/deutivacaftor (D-IVA) or D-IVA…
- Trial name
- NCT07283770
- Testing
- VX-581, D-IVA, TEZ
- Where
- United States
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- Vertex Pharmaceuticals Incorporated
Cystic Fibrosis, Pancreatic Exocrine Insufficiency
Study Investigating a Delayed-Release Pancrelipase in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis
This study will assess the safety and tolerability of pancrelipase delayed release capsules in subjects up to 6 years of age with Pancreatic Exocrine Insufficiency (PEI) due to Cystic Fibrosis.
- Trial name
- NCT00775528
- Testing
- Pancrelipase Delayed Release
- Where
- 12 sites in United States
- Volunteers
- 19 people
- Sponsor
- Solvay Pharmaceuticals
Idiopathic Pulmonary Fibrosis
A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care
The main purpose of this study was to see how GLPG1690 works together with the current standard treatment on your lung function and IPF disease in general.
- Trial name
- ISABELA2 (NCT03733444)
- Testing
- GLPG1690
- Where
- 132 sites in United States, Argentina and 13 more
- Volunteers
- 781 people
- Sponsor
- Lakefront Biotherapeutics NV
Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis
Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
To assess the safety of treatment with pirfenidone (up to 3600 mg/d) in patients with pulmonary fibrosis/idiopathic pulmonary fibrosis (PF/IPF).
- Trial name
- NCT00080223
- Testing
- Pirfenidone
- Where
- 27 sites in United States
- Volunteers
- 83 people
- Sponsor
- Genentech, Inc.